Active Protection
from Pathogens.
Singletto’s novel Oxafence® technology is being developed to meet the needs of healthcare, military, industry, and consumers – providing ongoing Active Protection™ from pathogens where it matters most.
Proven Science with Novel Applications
Singletto applies the proven principles of Photodynamic Therapy (PDT), long-used medically to treat cancer and skin disease, in novel ways to inactivate pathogens. Singletto’s Antimicrobial Photodynamic Inactivation (aPDI) technology can provide ongoing protection from dangerous pathogens, including SARS-CoV-2. Worldwide research, including the WHO-led DeMaND studies, continues to confirm the efficacy of aPDI technology. Click below to read about Singletto’s origin story and the research supporting our core technology.
Active Protection That Goes Further
Most current forms of pathogen protection only 1) trap or shield pathogens or 2) provide one-time disinfection. Very few protective technologies exist to actively destroy pathogens during and throughout product use or wear. Singletto’s Oxafence Active Protection technology can provide ongoing pathogen inactivation. Click below to read about our technology.
That Which Sustains Us, Can Also Protect Us
The air we breathe. The light by which we see. The materials we wear. Singletto harnesses the power of oxygen, light, and color to provide Active Protection™ from pathogens. The protective dyes/colorants in Oxafence absorb and transfer energy from ambient light to the oxygen in the air creating singlet oxygen. Singlet oxygen is well-known for its antimicrobial powers and ability to inactivate viruses and bacteria. Click below to read about the science behind our technology.
Innovation Never Stops
Singletto’s Oxafence technology is based on simple and proven principles, but innovation drives us. Singletto’s leadership team, partner labs, expert chemists, virologists, and researchers push research and technology development forward every day. We’re optimizing the technology for specific use cases, environments, and unmet needs – and we’re partnering with trusted brands to develop products with this pathogen-fighting technology.
Meet our Team
-
James Chen, MD
Chief Scientific Officer
-
Tom Lendvay, MD
Chief Medical Officer
-
John Bjornson
Chief Executive Officer
-
Mike Butler
Healthcare Executive
-
Lacey Duffy
Experience
-
Michelle Markus
Partnerships
-
Daniel Hoang
Operations
-
Paul Rolley
Commercialization
-
Chris Mores, ScD
Lab Director | Virology
-
Stephen Hahn, MD, FASTRO
Strategic Advisor
-
Belinda Heyne, PhD
Labs | Photochemistry
-
Tanner Clark, MD
Research
-
Michael Gale, PhD
Labs | Virology
-
David Evans, PhD
Labs | Virology
-
Ray Goodrich, PhD
Labs | Biophysical Chemistry
-
Ray Heacox
Communications